China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
You may also be interested in...
After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.
The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.
In the latest in a series of regulatory changes in China, the national drugs regulator has apparently been renamed the National Medical Products Administration (NMPA), while the country's essential drugs list has been expanded to include more oncology and pediatric drugs, which will be fully reimbursed.